Company news

Tempus AI, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tempus Reports Third Quarter 2026 Results

November 2, 2026

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

October 26, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

October 23, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

October 19, 2026

Tempus to Report Third Quarter 2026 Financial Results on November 2

October 15, 2026

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

October 13, 2026

Tempus Announces Multi-Year Collaboration with Moderna and Merck

October 7, 2026

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

October 1, 2026

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

September 28, 2026

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

September 21, 2026

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

September 11, 2026

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

September 9, 2026

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 4, 2026

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

August 24, 2026

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

August 4, 2026

Tempus Reports Second Quarter 2026 Results

July 29, 2026

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

July 21, 2026

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

July 20, 2026

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

July 16, 2026

Tempus to Report Second Quarter 2026 Financial Results on July 30

July 9, 2026

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

June 25, 2026

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

June 11, 2026

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 5, 2026

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

June 3, 2026

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

June 1, 2026

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 31, 2026

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 29, 2026

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 29, 2026

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29, 2026

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

May 29, 2026

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

May 28, 2026

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

May 27, 2026

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 26, 2026

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

May 21, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

May 13, 2026

Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution"

May 11, 2026

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

May 8, 2026

Tempus Reports First Quarter 2026 Results

May 4, 2026

Tempus to Host Inaugural Investor Day on May 29, 2026

April 29, 2026

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

April 28, 2026

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

April 23, 2026

Tempus to Report First Quarter 2026 Financial Results on May 5

April 21, 2026

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

April 14, 2026

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

April 13, 2026

Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care

April 13, 2026

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

April 12, 2026

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

April 8, 2026

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

March 31, 2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

March 17, 2026

Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.